Full Text View
Tabular View
No Study Results Posted
Related Studies
PEG-Interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery
This study has been completed.
Study NCT00276523   Information provided by National Cancer Institute (NCI)
First Received: January 12, 2006   Last Updated: February 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Head and Neck Cancer
Additional conditions recognized in this trial
Head and Neck Neoplasms
More general conditions related to this trial
Neoplasms
Neoplasms by Site
Interventions listed in this trial
PEG-interferon alfa-2b
conventional surgery
neoadjuvant therapy
Additional drug interventions recognized in this trial
Interferon Alfa-2a
Interferon Alfa-2b
Interferon-alpha
Interferons
Peginterferon alfa-2b
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services